AIM: To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus determine the dose range for future clinical studies. METHODS: This was a two-part randomized, placebo controlled study in healthy volunteers using a liquid formulation. Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days. Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and laboratory parameters were assessed. BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement. RESULTS:PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses. PRN1008 demonstrated a large volume of distribution, and a half-life of approximately 3-4 h. BTK occupancy of >90% was observed within 4 h after dosing in both single and multiple dose regimens, and was closely linked to maximum plasma concentration. BTK occupancy decay was slow (-1.6% h-1 ), and occupancy was sustained despite drug concentrations being undetectable. No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature. CONCLUSIONS:PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.
RCT Entities:
AIM: To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus determine the dose range for future clinical studies. METHODS: This was a two-part randomized, placebo controlled study in healthy volunteers using a liquid formulation. Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days. Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and laboratory parameters were assessed. BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement. RESULTS:PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses. PRN1008 demonstrated a large volume of distribution, and a half-life of approximately 3-4 h. BTK occupancy of >90% was observed within 4 h after dosing in both single and multiple dose regimens, and was closely linked to maximum plasma concentration. BTK occupancy decay was slow (-1.6% h-1 ), and occupancy was sustained despite drug concentrations being undetectable. No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature. CONCLUSIONS:PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.
Authors: Gabriela López-Herrera; Alexander Vargas-Hernández; Maria Edith González-Serrano; Laura Berrón-Ruiz; Juan Carlos Rodríguez-Alba; Francisco Espinosa-Rosales; Leopoldo Santos-Argumedo Journal: J Leukoc Biol Date: 2013-11-18 Impact factor: 4.962
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Daigen Xu; Yong Kim; Jennifer Postelnek; Minh Diem Vu; Dong-Qing Hu; Cheng Liao; Mike Bradshaw; Jonathan Hsu; Jun Zhang; Achal Pashine; Dinesh Srinivasan; John Woods; Anita Levin; Alison O'Mahony; Timothy D Owens; Yan Lou; Ronald J Hill; Satwant Narula; Julie DeMartino; Jay S Fine Journal: J Pharmacol Exp Ther Date: 2012-01-06 Impact factor: 4.030
Authors: Erica K Evans; Richland Tester; Sharon Aslanian; Russell Karp; Michael Sheets; Matthew T Labenski; Steven R Witowski; Heather Lounsbury; Prasoon Chaturvedi; Hormoz Mazdiyasni; Zhendong Zhu; Mariana Nacht; Martin I Freed; Russell C Petter; Alex Dubrovskiy; Juswinder Singh; William F Westlin Journal: J Pharmacol Exp Ther Date: 2013-05-24 Impact factor: 4.030
Authors: Betty Y Chang; Min Mei Huang; Michelle Francesco; Jun Chen; Jeremy Sokolove; Padmaja Magadala; William H Robinson; Joseph J Buggy Journal: Arthritis Res Ther Date: 2011-07-13 Impact factor: 5.156
Authors: Oliver Hantschel; Uwe Rix; Uwe Schmidt; Tilmann Bürckstümmer; Michael Kneidinger; Gregor Schütze; Jacques Colinge; Keiryn L Bennett; Wilfried Ellmeier; Peter Valent; Giulio Superti-Furga Journal: Proc Natl Acad Sci U S A Date: 2007-08-07 Impact factor: 11.205
Authors: Jack Hutcheson; Kamala Vanarsa; Anna Bashmakov; Simer Grewal; Deena Sajitharan; Betty Y Chang; Joseph J Buggy; Xin J Zhou; Yong Du; Anne B Satterthwaite; Chandra Mohan Journal: Arthritis Res Ther Date: 2012-11-08 Impact factor: 5.156
Authors: Patrick F Smith; Janakan Krishnarajah; Philip A Nunn; Ron J Hill; Dane Karr; D Tam; Mohammad Masjedizadeh; Jens O Funk; Steve G Gourlay Journal: Br J Clin Pharmacol Date: 2017-08-01 Impact factor: 4.335
Authors: Claire L Langrish; J Michael Bradshaw; Michelle R Francesco; Timothy D Owens; Yan Xing; Jin Shu; Jacob LaStant; Angelina Bisconte; Catherine Outerbridge; Stephen D White; Ronald J Hill; Ken A Brameld; David M Goldstein; Philip A Nunn Journal: J Immunol Date: 2021-03-05 Impact factor: 5.422
Authors: Jinmin Lee; Victoria P Werth; Russell P Hall; Rüdiger Eming; Janet A Fairley; David C Fajgenbaum; Karen E Harman; Marcel F Jonkman; Neil J Korman; Ralf J Ludwig; Dedee F Murrell; Philippe Musette; Haley B Naik; Christian D Sadik; Jun Yamagami; Marc L Yale; Aimee S Payne Journal: Front Med (Lausanne) Date: 2018-11-08